LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Preclinical research suggests that several derivatives of aromatic amino acids with antiglutamatergic properties including AMPA receptor antagonism and inhibition of glutamate release such as 3,5-dibromo-D-tyrosine and 3,5-dibromo-L-phenylalnine exhibit strong anticonvulsant effect in animal models suggesting use of these compounds as a novel class of antiepileptic drugs.
After World War II the foundation sent a team to West Germany to investigate how it could become involved in reconstructing the country. They focused on restoring democracy, especially regarding education and scientific research, with the long-term goal of reintegrating Germany into the Western world. The foundation also supported the early initiatives of Henry Kissinger, such as his directorship of Harvard's International Seminars (funded as well by the Central Intelligence Agency) and the early foreign policy magazine Confluence, both established by him while he was still a graduate student. In 2021, Rajiv J. Shah, president of the Rockefeller Foundation, released a statement condemning eugenics and supporting the anti-eugenics movement. He stated that
Vaccines typically contain attenuated, inactivated or dead organisms or purified products derived from them. There are several types of vaccines in use. These represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response.
Sources: en.wikipedia.org
According to the first option, the spent nuclear fuel is considered complete waste. After an interim storage (wet and dry), all the used fuel is directly disposed of in a deep geological repository. Several geological media and repository designs are being studied according to different natures of fuel and their burnup, radioactive inventory and decay heat generation. The assessment of a geological disposal is based on the multi-barrier approach, which combines multiple effects of engineered and natural barriers in order to delay potential long-lived radionuclide migrations to the biosphere over time. Reprocessing is the alternative option for the spent fuel after a long interim storage. The used fuel is not considered waste anymore but a future energy resource. A large amount of fertile uranium (
=== Indigenous Affairs === In the April 2019 budget, funding for the Ministry of Indigenous Affairs was cut in half. Minister Rickford released a May 9, 2019 statement saying that the Ontario Government was "committed to do everything in its authority to support the relocation" of the Kashechewan First Nation. which is located north of Fort Albany, Ontario on the James Bay coast. The community has had flooding and infrastructure problems for many years and in April 2019, had to evacuate 2,500 members by plane when a state of emergency was called again. APTN reported, in the presence of 300 community members, both the federal and provincial governments signed the Framework Agreement with Kashechewan First Nation to commit to moving the reserve. The federal Minister of Indigenous Services Seamus O'Regan said the relocation process would probably take about eight years to complete.
=== Designation process === The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive. The most recent grant application prepared by MD Anderson Cancer Center took 24 months to prepare and ran to 2,963 pages. Cancer centers must renew their status with the NIH every 5 years. The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director. Independent or freestanding cancer centers are entities unto themselves and are not considered to be part of a larger institution or university. The center’s administration controls all space, appointments and budgets. These institutions may have university affiliations, but they remain administratively and financially distinct. The NCI also supports Consortium Centers, wherein scientists and clinicians from multiple institutions enter into formal agreements to expand cancer research programs. Importantly, Consortium Partners are not themselves considered NCI-designated. The NCI has strict guidelines on how Consortium Partners can refer to their relationship with their parent Consortium Center.
== Biosynthesis == In Bacillus cereus, cereulide is biosynthesised by the non-ribosomal peptide synthetase of the heterodimer proteins CesA and CesB. In non-ribosomal peptide synthetase, individual amino acids are added, modified, and linked. Addition is facilitated by the adenylation (A) domain. Modification is accomplished by the ketoreductase (KR) and epimerization (E) domains. Finally, the growing peptides are linked by condensation domains. The transportation between domains is facilitated by a peptide carrier protein or thiolation (T) domain, which houses the growing peptide chain. Additionally, a thioesterase (TE) domain is used by the final module to cleave and cyclize the final peptide product. The peptides produced from both CesA and CesB are linked with an ester rather than amide bond; given the cyclic structure of cereulide, this cyclic ester (or lactone) linkage makes cereulide a depsipeptide. CesA is a 387 kDa heterodimer protein composed of CesA1 and CesA2 modules. CesA1 adds ketoisocaproic acid to the adenylation domain. The thiolation domain will then move the ketoisocaproic acid along the ketoreductase domain, which reduces ketoisocaproic acid into D-α-hydroxyisocaproic acid with the cofactor NADPH. In module CesA2, L-alanine is added to the adenylation domain. The condensation domain will facilitate a nucleophilic attack by the free amine on L-alanine onto the thioester of D-α-hydroxyisocaproic acid (D-HIC) on the CesA1 module. This event links the peptides and situates the growing peptide molecule on the thiolation domain of CesA2.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.